The effects of sodium bicarbonate and sodium citrate ingestion on 600 m running performance were assessed in 11 female track athletes and four trained female non-athletes. The subjects ingested either sodium bicarbonate (NaHCO3), sodium citrate or placebo approximately 2.5 hrs prior to the test runs in doses of 0.3 g/kg body weight in a double blind cross over design. Prior to and after exercise NaHCO3, H+, and lactate (HLa) concentrations were measured and running times were recorded. Pre- and post-experiment baseline testings were also performed. Data analysis was conducted using a Manova Repeated Measures design and dependent "t"-test. Although differences in running times were found 121.5 s, 119.9 s, 120.4 s in bicarbonate, citrate and placebo treatments respectively, they were not significant. The pH and concentrations of NaHCO3 were significantly elevated prior to and after the exercise when alkalinizing agents were ingested (p < 0.001). In bicarbonate treatment, prior to exercise pH was 7.40 and [NaHCO3] was 28.4 mEq/l, and after the exercise pH was 7.14 and [NaHCO3] was 17.9 mEq/l. In citrate treatment, prior to exercise pH was 7.40 and [NaHCO3] was 27.1 mEq/l, and after the exercise pH was 7.13 and [NaHCO3] was 16.6 mEq/l. There were no significant differences among the pre-exercise (2.3 mmol/l, 2.1 mmol/l, 2.2 mmol/l in bicarbonate, citrate and placebo treatments respectively) and after-exercise (11.8 mmol/l, 11.9 mmol/l, 11.0 mmol/l bicarbonate, citrate and placebo, respectively) HLa concentrations. This study demonstrated that, although alkali ingestion resulted in significant shifts in the blood acid-base balance, it failed to affect the 600 m running performance.
Download full-text PDF |
Source |
---|
Nutrients
January 2025
School of Medicine, Valencia Catholic University, C/Quevedo 2, 46001 Valencia, Spain.
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age and requires better treatment. -acetylcysteine (NAC) is known to be beneficial under such conditions owing to its antioxidant potential and insulin-sensitizing properties. The effect of NAC on the reproductive outcomes of PCOS patients was examined in this meta-analysis.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral bempedoic acid (NEXLETOL in the USA; Nilemdo in the EU) and the fixed dose combination (FDC) of bempedoic acid/ezetimibe (NEXLIZET in the USA; Nustendi in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease. A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate-citrate lyase enzyme in the cholesterol biosynthesis pathway. In the multinational phase III CLEAR Outcomes trial in statin-intolerant patients, once-daily bempedoic acid 180 mg significantly reduced the risk of the primary endpoint (a four-component major adverse CV event composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) compared with placebo.
View Article and Find Full Text PDFTransl Exerc Biomed
September 2024
Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Objectives: To examine the effect of the NAD precursor, nicotinic acid (NA), for improving skeletal muscle status in sedentary older people.
Methods: In a double-blind, randomised, placebo-controlled design, 18 sedentary yet otherwise healthy older (65-75 y) males were assigned to 2-weeks of NA (acipimox; 250 mg × 3 daily, n=8) or placebo (PLA, n=10) supplementation. At baseline, and after week 1 and week 2 of supplementation, a battery of functional, metabolic, and molecular readouts were measured.
Contemp Clin Trials Commun
December 2024
Center of Excellence in Nanomedicine, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Combating obesity is challenging, as anti-obesity compounds lose effectiveness or cause severe side effects when delivered via conventional routes. Thus, there is a need for new, effective treatment routes that are home-based and safe for long-term use. This double-blind, placebo-controlled clinical trial aimed to investigate the efficacy of a biocellulose transdermal patch containing α-lipoic acid (ALA), an anti-obesity compound, in reducing subcutaneous fat accumulation.
View Article and Find Full Text PDFPlacenta
January 2025
Department of Gynecology and Obstetrics, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, the Netherlands.
Introduction: Early onset fetal growth restriction is a common pregnancy complication with significant risk of perinatal mortality and morbidity. The most common etiology is placental insufficiency, reflected by several placental lesions that appear with fetal growth restriction. Placental immune cells are involved in almost all aspects of the development of the placenta and immune cell imbalances have been related to common pregnancy complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!